Clinical Trial Update: Deflazacort in Dysferlinopathies [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 clinical trials evaluating deflazacort for dysferlinopathies (Limb-girdle muscular dystrophy type 2B and Miyoshi myopathy) have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysferlinopathy
• Limb-girdle Muscular Dystrophy Type 2b
• Miyoshi Myopathy

Drugs mentioned

• DEFLAZACORT (Deflazacort)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: LGMD2B, Miyoshi Myopathy | Phase 2, Phase 3 | Status: COMPLETED